A Feb 2022 article from Alison Tonks, Clinical Editor for the British Medical Journal announces changes to the product warning sheet for the antidepressant paroxetine by the Food and Drug Administration (FDA) in the United States. 1
Where it had been promoted that withdrawal from the drug was safe and easy, in fact up to 7% of patients could experience withdrawal symptoms with some of these severe and prolonged.
“In fact, withdrawal symptoms such as bad dreams, paraesthesia, and dizziness occur in up to 7% of patients, according to the new product information. The warning also mentions anecdotal reports of agitation, sweating, and nausea and tells doctors to consider restarting treatment if symptoms become intolerable.”
Concurrent with the FDA warning, the International Federation of Pharmaceutical Manufacturers Associations stated the manufacturer, Glaxo Smith Kline had misled the public about paroxetine on US television in 2021.
With the difficulty of withdrawal from antidepressants ignored or knowledge of it actively suppressed until recent years vital information is finally becoming known.